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A 43-year-old male was transferred to our institute. His heart rhythm on admission was
ventricular ﬁbrillation (VF) which was successfully deﬁbrillated with a direct current shock
(DC). A diagnosis of short QT syndrome (SQTS) was made on the basis of an abnormally
short QT interval of 280ms during the sinus rhythm. During treatment for mild total
hypothermia, VF recurred repeatedly necessitating DCs. Nifekalant at a dose of 0.3mg/kg
was intravenously administered, the QT interval was prolonged from 280 to 370ms and VF
no longer recurred. Subsequently the patient underwent implantation of an implantable
cardioverter deﬁbrillator.
(J Arrhythmia 2009; 25: 214–218)
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Case Report
A 43-year-old male suddenly passed out while
working at his desk, and bystanders who witnessed it
immediately performed cardiopulmonary resuscita-
tion on him. Despite their eﬀorts, he did not regain
consciousness, and they then called for an ambu-
lance. The ambulance transferred him to the emer-
gency room of our institute. His cardiac rhythm upon
arrival was VF, and direct current shock (DC) was
immediately delivered, resulting in the resumption of
sinus rhythm (SR). Serum potassium and calcium
concentrations were 3.9 and 9.2mEq/L, respective-
ly, and arterial blood pH was 6.947. He then
underwent treatment for total mild hypothermia to
improve his cerebral status which had suﬀered from
brain damage caused by the cardiac arrest. The
patient had no history of cardiovascular disease
except for the paroxysmal atrial ﬁbrillation. There
was no history of sudden death in his family. He had
been undergoing treatment for pure red cell aplasia
for the past 10 years, and had received many blood
transfusions for his anemia. During the total mild
hypothermia (34 C), he had experienced repeated
VF attacks which necessitated DCs to regain SR. In
order to suppress the incidence of VF, nifekalant, a
pure Ikr blocker, was intravenously administered to
prolong his QT interval. Continuous intravenous
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nifekalant was started at a dose of 0.2mg/kg and
then increased to 0.4mg/kg. A routine 12-lead
electrocardiogram revealed SR with a signiﬁcant
prolongation of the QT interval from 280 to 370ms
(Bazett-corrected QT interval of 320–410ms). The
QT interval was measured from the onset of the Q
wave to the terminal portion of the T wave. The
conﬁguration of the QRS complex was similar to an
‘‘Osborn wave’’, and may have been associated with
the total hypothermia. Further, the slurring and
notching of the terminal portion of the QRS complex
might have been a manifestation of the transmural
electrical inhomogeneity leading to the serious
arrhythmias1) (Figure 1) and peaked T waves that
were observed as the nifekalant dose was increased
to 0.4mg/kg/hour. As the QT interval became
prolonged by the intravenous nifekalant, the inci-
dence of VF was signiﬁcantly suppressed (Figure 2).
The serum potassium concentration was maintained
within normal limits and ranged from 4.1 to
5.5 mmol/l throughout his clinical course. Nifekalant
was withdrawn when the QT interval signiﬁcantly
prolonged to a value of at least 350ms, and frequent
occurrence of VF was concomitantly and completely
suppressed. The QT interval was maintained at
approximately 370ms even after the withdrawal of
the nifekalant. After the total mild hypothermia, his
consciousness recovered to a normal level. He
underwent coronary angiography, ventriculography,
and a myocardial biopsy for further examination of
the etiology of his pathological status. The biopsy
specimen was obtained from the right ventricular
septum.
There was no evidence of abnormal coronary
arteries or left ventricular function. An electrophy-
siological study (EPS) was also performed in the
clinic to assess his VF 21 days after the cessation of
the intravenous nifekalant. The eﬀective refractory
period (ERP) of the ventricles was 160ms at a basic
cycle length of 600ms, which was measured through
the electrode catheter positioned at the right ven-
tricular apex. EPS was not performed at any other
ventricular location. VF was easily and repeatedly
induced by double ventricular extrastimuli (VPE) at
a basic cycle length of 600ms (Figure 3). EPS for the
assessment of the eﬀects of the antiarrhythmic
agents was not performed. Because the ERP of his
ventricles was too short, the coupling intervals of the
double VPE, which were able to provoke VF, were
170 and 160ms, respectively. He underwent im-
plantation of an implantable cardioverter deﬁbrilla-
tor (ICD). The diagnosis suggested by the myocar-
dial biopsy was myocardial hemochromatosis and
was characterized by deposits of hemosiderin in
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Figure 1 Twelve-lead electrocardiogram.
The QT interval was prolonged from 260ms (on admission: panel A) to 370ms (panel B) when intravenous nifekalant
was administered, and then shortened back to 300ms (panel C) when the nifekalant was withdrawn.
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the myocardium. The ejection fraction of the left
ventricle was approximately 57% calculated from
transthoracic echocardiography. A genetic screening
test was also given. The target genes were
KCNH2,2,3) KCNQ1,4) KCNJ2,5) as well as KCNE1
and KCNE2. However, as a result no mutations of
those genes were found. Twelve-lead ECG tracings
from his parents and children were examined, and no
abnormal ﬁndings were recognized.
Discussion
Unlike QT prolongation, an abbreviation of the
QT interval had not been considered to pose any
arrhythmic risk until the publication by Gussak
et al.6) identifying that phenotype as a new clinical
entity associated with an arrhythmic burden. In
addition, short QT interval is not associated with any
electrolyte imbalance or metabolic abnormality just
as was seen in the present case. In patients with a
prolonged QT interval, the Bazett correction formula
is used to assess the risk of a disastrous outcome;
however, Extramiana et al. demonstrated that the
formula was not appropriate for making a diagnosis
of SQTS because that method might induce a false
negative diagnosis of SQTS.7) Dumaine and Wolpert
also reported that the rate-adaptation of the QT
interval is abnormal in SQTS patients, and the QT
interval may appear normal at faster heart rates when
Bazett’s or other corrections are applied.8,9)
Gaita et al.10) tested the therapeutic eﬀects of
ﬂecainide, ibutilide, sotalol and quinidine in SQTS
patients, and they found that only quinidine pro-
duced normalization of the QT interval, T wave
morphology and ventricular ERP, which were
described as characteristics peculiar to SQTS by
Antzelevitch and Giustetto.11,12) They further sug-
gested that not only the blockade action of Ikr, but
also quinidine’s other properties were eﬀective for
treating SQTS. In our case, nifekalant, a pure Ikr
blocker, was eﬀective for dramatically suppressing
the electrical storms of VF, although it is possible
that the VF in the present case might have been
associated with the mild hypothermia provoking a
‘‘J wave’’ in the setting of the SQTS. In addition, we
were unable to completely exclude the possibility of
VF associated with hemochromatosis.13,14)
When we are looking for the acute eﬀects of a
drug on VF storms in STQS, this drug might be the
ﬁrst option for therapy. In particular, in patients who
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Figure 2 The clinical course in this case.
Since the QT interval was prolonged by the intravenous nifekalant, the incidence of VF signiﬁcantly decreased.
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are connected to artiﬁcial ventilators as in the present
case, the intravenous administration of antiarrhyth-
mic agents could be regarded as the sole therapeutic
option. Antiarrhythmic Ikr blocker agents such as
sotalol and quinidine could also be prescribed for
chronic prophylactic treatment for VF.
The diagnosis of hemochromatosis was made
according to the results of the myocardial biopsy.
However, to our knowledge, there are no reports of a
relationship between hemochromatosis and SQTS
associated with VF.
We considered the VF in the present case to be
unassociated with the electrolyte imbalance and the
metabolic acidosis.
In view of the generally insuﬃcient evidence of
the protective eﬀects of pharmacological interven-
tions, the possibility of terminating potentially life-
threatening episodes of malignant ventricular ta-
chyarrhythmias by electrical shocks delivered from
ICDs has become increasingly attractive.15) There-
fore, an appropriate risk stratiﬁcation provides a
rational basis for proposing an ICD implantation
with a reasonable risk-beneﬁt ratio. Although the
signiﬁcance of programmed pacing is unclear re-
garding the risk stratiﬁcation,12) we regarded the ease
and reproducibility of VF as signiﬁcant ﬁndings.
Therefore, we made a decision to implant an ICD in
this patient. Atrial ﬁbrillation (AF) may be the ﬁrst
symptom of SQTS, especially in relatively younger
patients with lone AF,16,17) and our patient also had
multiple episodes of AF. He was followed up for a
year, no shocks have been delivered up to the present
without the use of any antiarrhythmic agents. SQTS
is a rare, mechanistically heterogeneous and incom-
pletely understood disorder. The primary treatment
is an ICD implantation even though this is subopti-
mal. Despite agreement that eﬀective drug therapy
for SQTS is necessary, there are limited opportuni-
ties for clinical drug testing in this rare disease.
Nifekalant could be regarded as the ﬁrst line
antiarrhythmic agent for acute dysrrhythmic events
in short QT syndrome.
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